Québec Adds Bausch Health’s PrOKEDI to Public Drug Formulary for Schizophrenia Treatment
Event summary
- Bausch Health’s PrOKEDI® (extended-release risperidone) listed on Québec’s public drug formulary effective June 25, 2026.
- 75 mg and 100 mg strengths approved for schizophrenia treatment in adults.
- Listing follows successful negotiations with the Pan-Canadian Pharmaceutical Alliance (APP).
- PrOKEDI® achieves clinically relevant concentrations without loading dose or oral supplementation.
The big picture
Québec’s decision to list PrOKEDI® underscores the growing demand for innovative mental health treatments, particularly those that improve treatment continuity and reduce relapse risk in schizophrenia. This approval follows a broader trend of provincial healthcare systems prioritizing access to advanced therapies, though Bausch Health will need to navigate varying reimbursement processes across Canada to maximize market reach.
What we're watching
- Provincial Rollout
- Whether Bausch Health can secure similar reimbursement listings in other Canadian provinces.
- Market Penetration
- The pace at which PrOKEDI® gains adoption among psychiatrists and healthcare teams.
- Competitive Dynamics
- How this listing affects Bausch Health’s positioning against existing long-acting antipsychotics.
Related topics